pdufa.bio
Home › Decisions › RCKT 2026-03-27

RCKT FDA decision — Mar 27, 2026

✓ APPROVED

Rocket Pharmaceuticals Inc. — KRESLADI (marnetegragene autotemcel) · Leukocyte Adhesion Deficiency-I (LAD-I).

Run-up into the decision (T-120 → T+5)

PDUFA 3/27/26$5.3$2.8410/10/25
Daily close, T-120 (10/10/25) through T+5. Run-up high $5.3 on 3/10/26, low $2.84 on 11/27/25 (T-120 to T-1). FDA decision 3/27/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-27
OutcomeApproved
Drug / candidateKRESLADI (marnetegragene autotemcel)
CompanyRocket Pharmaceuticals Inc.
120-day run-up (T-120→T-1)+48.9%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio